<DOC>
	<DOCNO>NCT00006052</DOCNO>
	<brief_summary>RATIONALE : STI571 may interfere growth cancer cell may effective treatment chronic myelogenous leukemia . PURPOSE : Phase II trial study effectiveness STI571 treat patient accelerated phase chronic myelogenous leukemia .</brief_summary>
	<brief_title>STI571 Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety STI571 patient accelerate phase Philadelphia chromosome positive ( chromosome negative Bcr/Abl positive ) chronic myelogenous leukemia . II . Determine rate hematological response treatment patient . III . Determine improvements symptomatic parameter treatment patient . IV . Determine cytogenetic response treatment patient . V. Determine time treatment failure patient receive treatment . OUTLINE : Patients receive oral STI571 daily . Treatment continue least 1 year absence disease progression unacceptable toxicity . Patients consider benefit may continue treatment beyond 1 year . PROJECTED ACCRUAL : Not determine</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis chronic myelogenous leukemia accelerate phase At least 15 % le 30 % blast blood bone marrow At least 30 % blast plus promyelocytes peripheral blood bone marrow At least 20 % peripheral basophil Thrombocyte count le 100,000/mm3 ( unrelated therapy ) Patients must never blastic phase Ph chromosome positive OR Ph chromosome negative Bcr/Abl positive PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 03 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Blood count recover prior antileukemic agent Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) ( great 3 time ULN liver involvement suspect ) AST ALT great 3 time ULN ( great 5 time ULN liver involvement suspect ) Renal : Creatinine great 2 time ULN Cardiovascular : No grade 3 4 cardiac disease Other : No serious concurrent medical condition Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception least 2 week study woman least 3 month study men No history noncompliance medical regimen PRIOR CONCURRENT THERAPY : Biologic therapy : At least 48 hour since prior interferon alfa Prior hematopoietic stem cell transplantation allow blood count recover No concurrent biologic therapy Chemotherapy : At least 14 day since prior homoharringtonine At least 24 hour since prior hydroxyurea At least 7 day since prior low dose cytarabine ( le 30 mg/m2 every 1224 hour daily ) At least 14 day since prior moderate dose cytarabine ( 100200 mg/m2 57 day ) At least 28 day since prior high dose cytarabine ( 13 g/m2 every 1224 hour 612 dos ) At least 21 day since prior anthracyclines , mitoxantrone , etoposide , methotrexate , cyclophosphamide At least 6 week since prior busulfan No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : At least 28 day since prior investigational agent No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
</DOC>